Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (71-80 of 154) with videos related to

Pageof 16
Sort By:
Critical Reviews in Oncology/Hematology|January 22, 2021
Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and educationClaudia Sorce, Agnieszka Chalaszczyk, Francesca Rossi, et al.
Oncotarget|October 21, 2016
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiationFrancesca Megiorni, Simona Camero, Simona Ceccarelli, et al.
Molecular and Cellular Biology|July 4, 2007
ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic programMichele Pelosi, Francesco Marampon, Bianca M Zani, et al.
International Journal of Molecular Sciences|January 16, 2021
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell LineViviana M Bimonte, Francesco Marampon, Ambra Antonioni, et al.
Journal of Hypertension|July 23, 2013
Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axisFrancesco Marampon, Giovanni L Gravina, Luca Scarsella, et al.
Molecular Cancer|February 22, 2016
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell populationCarmela Ciccarelli, Francesca Vulcano, Luisa Milazzo, et al.
International Journal of Molecular Sciences|April 3, 2021
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 InhibitionClarissa Corinaldesi, Rebecca L Ross, Giuseppina Abignano, et al.
Cancer Letters|March 23, 2020
BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cellsSimona Camero, Lucrezia Camicia, Francesco Marampon, et al.
Cancers|January 21, 2022
ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human GlioblastomaGiovanni Luca Gravina, Alessandro Colapietro, Andrea Mancini, et al.
Biochemical Pharmacology|September 9, 2025
Didox, a ribonucleotide reductase inhibitor with iron chelator properties, counteracts the in vitro and in vivo growth of rhabdomyosarcoma cellsLuca Cantamessa, Michela Asperti, Magdalena Gryzik, et al.
Pageof 16

Showing results (71-80 of 154) with videos related to

Sort By:
Pageof 16
Critical Reviews in Oncology/Hematology|January 22, 2021
Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and educationClaudia Sorce, Agnieszka Chalaszczyk, Francesca Rossi, et al.
Oncotarget|October 21, 2016
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiationFrancesca Megiorni, Simona Camero, Simona Ceccarelli, et al.
Molecular and Cellular Biology|July 4, 2007
ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic programMichele Pelosi, Francesco Marampon, Bianca M Zani, et al.
International Journal of Molecular Sciences|January 16, 2021
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell LineViviana M Bimonte, Francesco Marampon, Ambra Antonioni, et al.
Journal of Hypertension|July 23, 2013
Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axisFrancesco Marampon, Giovanni L Gravina, Luca Scarsella, et al.
Molecular Cancer|February 22, 2016
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell populationCarmela Ciccarelli, Francesca Vulcano, Luisa Milazzo, et al.
International Journal of Molecular Sciences|April 3, 2021
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 InhibitionClarissa Corinaldesi, Rebecca L Ross, Giuseppina Abignano, et al.
Cancer Letters|March 23, 2020
BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cellsSimona Camero, Lucrezia Camicia, Francesco Marampon, et al.
Cancers|January 21, 2022
ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human GlioblastomaGiovanni Luca Gravina, Alessandro Colapietro, Andrea Mancini, et al.
Biochemical Pharmacology|September 9, 2025
Didox, a ribonucleotide reductase inhibitor with iron chelator properties, counteracts the in vitro and in vivo growth of rhabdomyosarcoma cellsLuca Cantamessa, Michela Asperti, Magdalena Gryzik, et al.
Pageof 16